CURE Childhood Cancer is dedicated to discovering a cure for childhood cancer through cutting edge research and providing support to patients and their families through our innovative programming.
Since its inception in 1975, CURE has focused on improving the care, quality of life, and survival rate of children with cancer. The founders – parents and a dedicated pediatric oncologist – joined forces to support laboratory research that would translate into immediate care for children with cancer.
Research is at the core of CURE’s drive to cure childhood cancer. The accomplishments of childhood cancer research teams across the U.S. and the world have made excellent inroads into understanding how to fight this devastating disease. Since the mid-1950s, survival rates have risen from less than 10 percent to almost 80% overall for children with cancer.
The objective of this White Paper is to help you understand the basics of childhood cancer – where we have come from and the challenges ahead in curing this horrible disease. The content of this document has been sourced from the primary children’s cancer research centers including CureSearch (uniting the Children’s Oncology Group and the National Childhood Cancer Foundation), the National Cancer Institute and the National Institute of Health. While this white paper provides a good starting point in helping you understand the challenges ahead, we encourage you to visit the websites of these organizations and institutions for more details.
You will see that while we have made excellent progress, we have a lot more to do in letting children live cancer free.
Click here to view the full White Paper. A very special thank you to Board of Director Vice President, Don Campbell for writing the white paper and Board of Director member Kevin Karem and Advisory Board member, Dr. Harry Findley for their contributions as well.
CURE Childhood Cancer is proud to welcome Kevin Karem as a new member of our Board of Directors. Karem is currently a Microbiologist for the Center for Disease Control (CDC) and has been an important addition to our team of Directors.
